

15 January 2026

Multiple Sclerosis Treatments

Question One:

How many patients has your trust treated in the past six months (for any disease) with the following drugs:

Drug Name	Patient Numbers
Aubagio (teriflunomide)	91
Avonex (interferon beta-1a)	27
Betaferon (interferon beta-1b)	<5
Brabio (glatiramer acetate)	0
Copaxone (glatiramer acetate)	44
Extavia (beta interferon-1b)	0
Gilenya (fingolimod)	0
Kesimpta (ofatumumab)	39
Lemtrada (alemtuzumab)	0
Mavenclad (cladribine)	0
Mayzent (siponimod)	15
Ocrevus (ocrelizumab)	201
Plegridy (peginterferon beta-1a)	17
Ponvory (ponesimod)	0
Rebif (beta interferon-1a)	16
Tecfidera (dimethyl fumarate)	244
Tysabri (natalizumab)	102
Tysabri (natalizumab) Pre-filled syringes only	103
Vumerity (diroximel fumarate)	25
Zeposia (ozanimod)	0
Fingolimod generic	50
Tyruko (Natalizumab Biosimilar)	0
Briumvi (ublituximab)	0

15 January 2026

Question Two:

How many patients has your trust treated with Rituximab for MS (Multiple Sclerosis) in the past six months? 0

Question Three:

How many patients within your trust have a diagnosis of MS (Multiple Sclerosis)? 2728

Question Four:

Of the patients with a diagnosis of Multiple Sclerosis, how many patients have a diagnosis of:

Condition	Patient Numbers
RRMS – Relapse Remitting Multiple Sclerosis	1760
PPMS – Primary Progressive Multiple Sclerosis	119
SPMS – Secondary Progressive Multiple Sclerosis	415

Please note that the totals in question 4 do not add up to the grand total in question 3 because it is not always clear the specific type of MS a patient may have – diagnosis may just be recorded as MS and not specific at this stage to the 3 types listed.

Use of <5 (less than five): We are unable to provide an exact figure - exempt from release under Section 40(2) of the Freedom of Information Act - Personal Information relating to a third party, as the small numbers involved could make patients personally identifiable. Disclosure would constitute a breach of the principles of the General Data Protection Regulation 2018.